Comment by Detrytus
3 years ago
But you would need much more participants in all trials, to make up for all those new combos that you now have to consider.
Also: I can imagine that most of the patients would be eager to engage in all possible treatments. You might not even have a control group that did not participate in the study of the faulty drug X
Then all you get is data about the effectiveness of XY. Would it be any better if only X was tested, but it turned out that that one drug 'X' contained two separate active ingredients, each of which the pharmaceutical company thought would probably be an effective treatment?